A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

NCT01047007 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped The study has been terminated due to business reasons.

Conditions

Solid Tumors

Interventions

DRUG: adavosertib 20 mg
DRUG: 5-FU 1000 mg/m^2/day
DRUG: CDDP
DRUG: adavosertib 65 mg

Sponsor

Merck Sharp & Dohme LLC